Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

8,848 13,470 15,789 25,345 152,987 General and administrative 5,118 5,223 10,305 10,419 68,154 Impairment of leasehold improvements - - - - 1,030 Depreciation and amortization 332 519 653 1,024 5,311 In-process research and development - - - - 418 Total operating expenses 14,298 19,212 26,747 36,788 227,900 Loss from operations (10,491) (13,851) (19,779) (26,819) (201,181) Other income (expenses): Interest income 1,331 269 3,034 795 13,555 Interest expense (59) (41) (129) (71) (1,718) Change in fair value of warrant liability - - - - (454) Other expense - - - - (1,180) Loss before tax benefit (9,219) (13,623) (16,874) (26,095) (190,978) (Provision for)/ benefit from income taxes (75) - (150) - 695 Net loss (9,294) (13,623) (17,024) (26,095) (190,283) Deemed dividend - - - - (19,424) Preferred stock accretion - - - - (802) Net loss attributable to common stockholders $(9,294) $(13,623) $(17,024) $(26,095)$(210,509) Net loss attributable to common stockholders per common share - basic and diluted $(0.41) $(0.60) $(0.76) $(1.15) Weighted-average common shares outstanding - basic and diluted 22,467,198 22,618,026 22,439,893 22,615,951


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 The new , Healthcare ... , available today on PharmaBoardroom.com for free ... that rocked the Spanish economy in 2009, and the austerity ... has remained pragmatic in times of trouble. "Despite ... fifth biggest European market, and the general conditions to invest ...
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... HARBOR, Mich. , Sept. 18, 2014  Health Enhancement ... biotech firm investigating early-stage algae bioactive compounds and metabolic processes, ... to the company,s board of directors. Ms. Nola E. ... and investment advisor joined the board effective September 17, 2014. ... Ms. Masterson agree to join our board," states Andrew ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 On Tuesday, ... and Sen. Jim Risch for National Lab Day on ... from across the national laboratory system. Durbin and Risch ... aims to increase awareness of the reach of the ... and discoveries to address some of our nation's most ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3POCT Market in China 2014-2018 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3
... (Nasdaq: PBIO ) ("PBI" or the "Company") today ... was $334,041 compared to $174,071 for the comparable period in ... PCT products and services was $233,256 for the three months ... period in 2007, a 97% increase. During the fourth ...
... 4 Tigris Pharmaceuticals, Inc., a privately held ... New Drug (IND) application for the Company,s geranylgeranyltransferase ... Food and Drug Administration. This will allow the ... the safety of GGTI-2418 during the first quarter ...
... Head of Nektar Therapeutic,s Pulmonary Business Unit, Among ... Savara, Inc., a biopharmaceutical company developing novel ... today announced that it has expanded its Board ... Elam, former head of the pulmonary business unit ...
Cached Biology Technology:Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 3Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 4Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 5Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 6Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 7Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 8FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418 2Savara Expands Board of Directors, Appoints Three New Members 2Savara Expands Board of Directors, Appoints Three New Members 3
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
(Date:9/18/2014)... cycles of carbon and nitrogen comprise all spheres ... environmental systems have caused imbalances and perturbations that ... (GHGs). Increased GHGs result in climate changes which ... oceans and the atmosphere. Understanding these feedback mechanisms ... of environmental science during the past three decades. ...
(Date:9/18/2014)... are too stressed they are often grouchy, grumpy, nasty, ... (BMI) at EPFL have just highlighted a fundamental synaptic ... the loss of social skills and cognitive impairment. When ... molecule in the brain. This was revealed by a ... Carmen Sandi,s team went to look for answers in ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Greenhouse gas research enters a new era 2How stress tears us apart 2
... looking good for him. Up until now he has been in ... he finishes first is often decided by just a few seconds. ... on the cross-country ski run, the condition of the athlete on ... Olympic skiing stars who are wooed by sponsors, up until now ...
... that celiac disease is increasing in prevalence because farmers are ... conclusion of an article in the ACS, Journal of ... evidence that the incidence of celiac disease increased during the ... the disease is 4 times more common today. Also known ...
... Michael Pogue, a Research Entomologist in the ARS ... , Washington, DC, was sent a series of moth ... under consideration as a possible biocontrol agent for the ... species was initially identified as a common species, but ...
Cached Biology News:Optimized custom-made ski sledges 2Optimized custom-made ski sledges 3Biocontrol research on Brazilian peppertree in Florida discovers new cryptic species 2